For instance, both NEPC and SCLC share common genetic alterations (e.g., TP53/RB1/PTEN loss, MYC amplification), expression of NE master TFs (e.g., ASCL1, NEUROD1, FOXA2, SOX2), epigenetic alterations (e.g., DNMT, EZH2), the surface markers (e.g., DLL3, TROP2, FGFR), secreted protein (UCHL1), and nuclear exporter (XPO1) overexpression. This evidence concerns the gene ASCL1 and small cell lung carcinoma.